Markets:

Overview

News

Currencies

International

Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

311.21 -4.88 (-1.54%)

Streaming Delayed Price Updated: 9:58 AM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look ↗

February 14, 2026

Boot Barn Holdings operates over 500 stores nationwide, supplying western and workwear apparel to a diverse U.S. customer base.

Via The Motley Fool

Topics Regulatory Compliance

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.

Via Investor's Business Daily

This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know ↗

November 17, 2025

A high-conviction fund just trimmed one of its biggest winners—here’s what long-term investors should make of the move.

Via The Motley Fool

Topics Regulatory Compliance

Why One Small-Cap Fund Bought $11 Million in Cellebrite Stock Last Quarter ↗

November 17, 2025

A specialist small-cap fund just doubled down on a digital-intelligence company that's underperforming the broader market.

Via The Motley Fool

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

This Fund Cut $7.3 Million of Atlas Energy Stock as the Company Suspends Its Dividend to Help Fuel Growth ↗

November 17, 2025

One fund just took a step back from a struggling energy name—right as the company suspended its dividend to fund future growth.

Via The Motley Fool

Topics Economy Regulatory Compliance

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

November 10, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch ↗

November 07, 2025

Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.

Via Benzinga

Ligand (LGND) Q3 2025 Earnings Call Transcript ↗

November 06, 2025

Ligand (LGND) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

Ligand Pharmaceuticals (NASDAQ:LGND) Surges on Strong Q3 2025 Earnings Beat and Raised Guidance ↗

November 06, 2025

Ligand (LGND) smashed Q3 2025 earnings estimates, driven by 47% royalty growth. The company also raised its full-year 2025 revenue and EPS guidance.

Via Chartmill

Topics Earnings

What's Next: Ligand Pharmaceuticals's Earnings Preview ↗

November 05, 2025

Via Benzinga

Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance

September 22, 2025

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

What Analysts Are Saying About Ligand Pharmaceuticals Stock ↗

September 02, 2025

Via Benzinga

Ligand (LGND) Q2 Revenue Jumps 15% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

Ligand Pharmaceuticals (NASDAQ:LGND) Surpasses Q2 2025 Earnings Estimates with Strong Royalty Growth ↗

August 07, 2025

Ligand Pharmaceuticals (LGND) beat Q2 2025 earnings estimates with strong royalty growth, raising full-year guidance. Stock dipped slightly pre-market but gained 16.3% over the past month.

Via Chartmill

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

July 31, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts ↗

July 10, 2025

The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.

Via Stocktwits

Topics Government

Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease ↗

July 10, 2025

Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.

Via Benzinga

Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday ↗

July 09, 2025

Via Benzinga

Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings ↗

April 17, 2025

Via Benzinga

Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated ↗

April 17, 2025

Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.

Via Stocktwits

Dow Falls Over 1%; US Initial Jobless Claims Decline ↗

April 17, 2025

Via Benzinga

Topics Stocks

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity ↗

April 17, 2025

Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.

Via Benzinga

Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy ↗

April 10, 2025

Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.

Via Benzinga

This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

April 10, 2025

Via Benzinga

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

February 13, 2025

From Ligand Pharmaceuticals Incorporated

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.